-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dr.
The study abstract was first published by Dr.
The study suggests that in the overall population, 65% of patients assessed as low-risk EPclin, 97% of 10-year DRFS, and 76% of high-risk patients with DRFS;
In the lymph node-positive subgroup, EPclin was assessed as low-risk for 19% of patients and 100% of 10-year DRFS, demonstrating that EndoPredict can accurately prognosis in premenopausal patient populations regardless of whether nodes are negative or positive
In addition, the results of another exploratory subgroup analysis of the study showed that in patients assessed as low-risk in EPclin, patients with 10-year DRFS were similar, less than 5%,
In response to the study's published data, Dr.
Based on this, Dr.